Tags

Type your tag names separated by a space and hit enter

[Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
J Cardiol. 2000 Apr; 35(4):277-85.JC

Abstract

Lowering the blood cholesterol level is a safe method to improve survival for primary and secondary prevention of coronary heart disease. However, there is no evidence for any effectiveness in Japanese. This study was designed to evaluate the effect of cholesterol lowering therapy with 3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA) reductase inhibitor on cardiac events(death and reinfarction) in Japanese patients after myocardial infarction. A total of 290 patients after myocardial infarction were studied retrospectively. The patients were divided into 2 groups with or without HMG-CoA reductase inhibitor therapy for lowering blood cholesterol levels. The cumulative cardiac events and percentage change of cholesterol levels[total cholesterol and low-density lipoprotein (LDL) cholesterol level] were compared between the 2 groups. HMG-CoA reductase inhibitor therapy lowered plasma cholesterol levels significantly (total cholesterol level--11 +/- 20%, LDL cholesterol level--23 +/- 26%) in patients with hypercholesterolemia, whereas there was no change(total cholesterol level 4.3 +/- 22%, LDL cholesterol level--7.2 +/- 24%) in patients without hypercholesterolemia. HMG-CoA reductase inhibitor therapy reduced cardiac events significantly compared in patients with hypercholesterolemia(p = 0.0008), but there was no benefit in patients without hypercholesterolemia. We suggest that treatment with HMG-CoA reductase inhibitor therapy for lowering cholesterol levels was effective for secondary prevention after myocardial infarction in Japanese patients with hypercholesterolemia.

Authors+Show Affiliations

Department of Cardiology, Surugadai Nihon University Hospital, Tokyo.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article

Language

jpn

PubMed ID

10791271

Citation

Tachibana, E, et al. "[Effect of Cholesterol Reducing Therapy With 3-hydroxy-3-methylglutaryl Coenzyme a Reductase Inhibitor On Secondary Prevention After Myocardial Infarction in Japanese Patients]." Journal of Cardiology, vol. 35, no. 4, 2000, pp. 277-85.
Tachibana E, Watanabe I, Nagao K, et al. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]. J Cardiol. 2000;35(4):277-85.
Tachibana, E., Watanabe, I., Nagao, K., & Kanmatsuse, K. (2000). [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]. Journal of Cardiology, 35(4), 277-85.
Tachibana E, et al. [Effect of Cholesterol Reducing Therapy With 3-hydroxy-3-methylglutaryl Coenzyme a Reductase Inhibitor On Secondary Prevention After Myocardial Infarction in Japanese Patients]. J Cardiol. 2000;35(4):277-85. PubMed PMID: 10791271.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]. AU - Tachibana,E, AU - Watanabe,I, AU - Nagao,K, AU - Kanmatsuse,K, PY - 2000/5/3/pubmed PY - 2000/7/15/medline PY - 2000/5/3/entrez SP - 277 EP - 85 JF - Journal of cardiology JO - J Cardiol VL - 35 IS - 4 N2 - Lowering the blood cholesterol level is a safe method to improve survival for primary and secondary prevention of coronary heart disease. However, there is no evidence for any effectiveness in Japanese. This study was designed to evaluate the effect of cholesterol lowering therapy with 3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA) reductase inhibitor on cardiac events(death and reinfarction) in Japanese patients after myocardial infarction. A total of 290 patients after myocardial infarction were studied retrospectively. The patients were divided into 2 groups with or without HMG-CoA reductase inhibitor therapy for lowering blood cholesterol levels. The cumulative cardiac events and percentage change of cholesterol levels[total cholesterol and low-density lipoprotein (LDL) cholesterol level] were compared between the 2 groups. HMG-CoA reductase inhibitor therapy lowered plasma cholesterol levels significantly (total cholesterol level--11 +/- 20%, LDL cholesterol level--23 +/- 26%) in patients with hypercholesterolemia, whereas there was no change(total cholesterol level 4.3 +/- 22%, LDL cholesterol level--7.2 +/- 24%) in patients without hypercholesterolemia. HMG-CoA reductase inhibitor therapy reduced cardiac events significantly compared in patients with hypercholesterolemia(p = 0.0008), but there was no benefit in patients without hypercholesterolemia. We suggest that treatment with HMG-CoA reductase inhibitor therapy for lowering cholesterol levels was effective for secondary prevention after myocardial infarction in Japanese patients with hypercholesterolemia. SN - 0914-5087 UR - https://www.unboundmedicine.com/medline/citation/10791271/[Effect_of_cholesterol_reducing_therapy_with_3_hydroxy_3_methylglutaryl_coenzyme_A_reductase_inhibitor_on_secondary_prevention_after_myocardial_infarction_in_Japanese_patients]_ L2 - https://medlineplus.gov/heartattack.html DB - PRIME DP - Unbound Medicine ER -